Proinflammatory mediators in lipid emulsions and parenteral nutrition–associated liver disease: Review of leading factors

• Published in: JPEN. Journal of parenteral and enteral nutrition 2023-08, Vol.47 (6), p.710-717
• Main Author: Driscoll, David F.
• Format: Article
• Language: English
• Subjects: fatty acids; lipids; parenteral nutrition
• ISSN: 0148-6071; 1941-2444
• DOI: 10.1002/jpen.2507

Lipid injectable emulsions have been in clinical use for over 60 years. The first product launched was Intralipid, which consisted of an emulsion of soybean oil in water for intravenous administration. It was a key source of essential fatty acids and an alternative source of energy for patients with gastrointestinal dysfunction requiring long‐term parenteral nutrition. With clinical experience, a condition known as parenteral nutrition–associated liver disease (PNALD), or intestinal failure–associated liver disease (IFALD), was observed, with a focus on carbohydrate and fat energy. Modifying the daily doses and infusion rates had some salutary effects, but PNALD persisted. Subsequently, on closer inspection of the fatty acids profile and phytosterol concentrations, degradation products arising from chemical and physical stability issues of the available lipid injectable emulsions were implicated. Recently, the US Food and Drug Administration convened an online workshop entitled “The Role of Phytosterols in PNALD/IFALD,” with an emphasis on (1) the multifactorial pathophysiology of PNALD/IFALD, (2) risk associated with phytosterols, and (3) regulatory history. The scope of this review includes the multifactorial pathophysiology of PNALD/IFALD as it relates to the pharmaceutical aspects of the various lipid injectable emulsions on the market, with respect to potential proinflammatory components, as well as physical and chemical stability issues that may also affect products' safe intravenous administration to patients.